Free Trial

Avalon GloboCare (ALBT) Competitors

+0.02 (+7.25%)
(As of 05/24/2024 ET)


Should you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Gamida Cell (GMDAQ), TC Biopharm (TCBP), Finch Therapeutics Group (FNCH), Eloxx Pharmaceuticals (ELOX), Windtree Therapeutics (WINT), TRACON Pharmaceuticals (TCON), Kiromic BioPharma (KRBP), Palisade Bio (PALI), Acorda Therapeutics (ACORQ), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "biological products, except diagnostic" industry.

Avalon GloboCare vs.

Avalon GloboCare (NASDAQ:ALBT) and Gamida Cell (NASDAQ:GMDAQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.

In the previous week, Avalon GloboCare had 2 more articles in the media than Gamida Cell. MarketBeat recorded 3 mentions for Avalon GloboCare and 1 mentions for Gamida Cell. Gamida Cell's average media sentiment score of 1.08 beat Avalon GloboCare's score of 0.86 indicating that Gamida Cell is being referred to more favorably in the news media.

Company Overall Sentiment
Avalon GloboCare Positive
Gamida Cell Positive

Avalon GloboCare and Gamida Cell both received 0 outperform votes by MarketBeat users.

Avalon GloboCareN/AN/A
Gamida CellN/AN/A

Avalon GloboCare has higher earnings, but lower revenue than Gamida Cell. Avalon GloboCare is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalon GloboCare$1.26M2.61-$16.71M-$1.57-0.19
Gamida Cell$1.78M1.47-$63M-$0.49-0.03

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalon GloboCare
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
Gamida Cell
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)

1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 50.3% of Gamida Cell shares are held by institutional investors. 64.0% of Avalon GloboCare shares are held by company insiders. Comparatively, 6.7% of Gamida Cell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Avalon GloboCare has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.

Gamida Cell has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,304.14%.

Company Net Margins Return on Equity Return on Assets
Avalon GloboCare-1,304.14% N/A -58.40%
Gamida Cell N/A N/A -55.93%


Gamida Cell beats Avalon GloboCare on 8 of the 12 factors compared between the two stocks.

Get Avalon GloboCare News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALBT vs. The Competition

MetricAvalon GloboCareBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.28M$2.94B$5.18B$8.06B
Dividend YieldN/A2.24%2.76%3.95%
P/E Ratio-0.1911.15104.4514.77
Price / Sales2.61364.072,516.2878.16
Price / CashN/A162.8535.9931.33
Price / Book-0.266.865.414.56
Net Income-$16.71M-$45.88M$106.26M$214.11M
7 Day Performance6.17%-2.69%-1.30%-1.04%
1 Month Performance8.43%5.74%2.72%3.13%
1 Year Performance-83.00%3.20%4.83%7.38%

Avalon GloboCare Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Gamida Cell
0 of 5 stars
N/AN/A$3.08M$1.78M-0.03N/AGap Up
TC Biopharm
0 of 5 stars
N/A-99.3%$3.71M$4.76M0.0041Gap Up
Finch Therapeutics Group
0.6696 of 5 stars
N/A-78.9%$3.74M$110,000.00-0.231News Coverage
Eloxx Pharmaceuticals
0.2707 of 5 stars
-89.0%$2.52MN/A-0.0918Gap Down
Windtree Therapeutics
0 of 5 stars
TRACON Pharmaceuticals
1.8821 of 5 stars
-87.6%$3.99M$12.05M2.2217Gap Up
Kiromic BioPharma
0 of 5 stars
N/A-18.8%$4.97MN/A-0.3335Gap Up
Palisade Bio
1.219 of 5 stars
-75.4%$5.08M$250,000.00-0.239Gap Down
Acorda Therapeutics
0 of 5 stars
N/AN/A$1.05M$117.63M0.00102Gap Down
Fresh Tracks Therapeutics
0 of 5 stars
N/A+51.6%$5.49M$8.01M-0.654News Coverage

Related Companies and Tools

This page (NASDAQ:ALBT) was last updated on 5/26/2024 by Staff

From Our Partners